<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777478</url>
  </required_header>
  <id_info>
    <org_study_id>UMCNONCO20083</org_study_id>
    <nct_id>NCT00777478</nct_id>
  </id_info>
  <brief_title>Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer</brief_title>
  <acronym>sutent-capiri</acronym>
  <official_title>A Phase I Dose Escalation Study With Sunitinib (SutentR) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this Phase 1 study is to identify the recommended dose of capiri and&#xD;
      of sunitinib for combination therapy subsequent phase II trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>after every completed doselevel</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine the safety and toxicity profile using the CTCAE criteria.</measure>
    <time_frame>after every completed doselevel</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capiri-sutent</intervention_name>
    <description>A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proof of colorectal cancer&#xD;
&#xD;
          -  Patients should have failed one previous line of systemic treatment for advanced&#xD;
             disease (and not more than one treatment line), either with fluoropyrimidine&#xD;
             monotherapy or in combination with oxaliplatin and/or bevacizumab.&#xD;
&#xD;
          -  No prior treatment with irinotecan or sunitinib&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  WHO PS 0-1 (see Appendix 3, corresponding with Karnofsky ≥ 70% )&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No measurable disease according to RECIST criteria.&#xD;
&#xD;
          -  Prior anti-cancer therapy &lt; 3 weeks before first dose. For cetuximab &lt; 30 days or&#xD;
             bevacizumab &lt; 60 days prior to the first dose.&#xD;
&#xD;
          -  Unresolved toxicity &gt; CTC gr 1 from previous anti-cancer therapy (including&#xD;
             radiotherapy) except for alopecia.&#xD;
&#xD;
          -  Inadequate bone marrow function (Hb ≤ 5.6 mmol/L, absolute neutrophil count (ANC) ≤&#xD;
             1.5 x 109/L, platelets ≤100 x 109/L)&#xD;
&#xD;
          -  renal dysfunction (serum creatinine ≥ 1.5x ULN and glomerular filtration rate ≤ 50&#xD;
             ml/min)&#xD;
&#xD;
          -  Prothrombin time (PT) and activated partial thromboplastin time (APTT) &gt; 2x ULRR&#xD;
&#xD;
          -  Hepatic dysfunction (serum bilirubin ≥ 1.5x ULN, serum transaminases ≥ 2.5 x ULN)&#xD;
&#xD;
          -  Greater than +1 proteinuria on two consecutive dipsticks taken no less then 2 weeks&#xD;
             apart unless urinary protein &lt; 1,5 g in a 24 Hr period.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History of clinical signs/symptoms of CNS metastases&#xD;
&#xD;
          -  Previous intolerance of fluoropyrimidine therapy, known dihydropyrimidine&#xD;
             dehydrogenase (DPD) deficiency. Known hypersensitivity to irinotecan or sunitinib of&#xD;
             their excipients.&#xD;
&#xD;
          -  No major surgery &lt; 4 weeks prior to study entry.&#xD;
&#xD;
          -  No radiotherapy &lt; 4 weeks prior to study entry except for palliative radiotherapy at&#xD;
             focal sites.&#xD;
&#xD;
          -  Any evidence of concurrent severe or uncontrolled disease (i.e. uncontrolled&#xD;
             hypertension, congestive heart failure, myocardial infarction &lt; 6 months, chronic&#xD;
             active infection, poorly regulated diabetes mellitus)&#xD;
&#xD;
          -  Any previous significant cardiovascular event during previous fluoropyrimidine therapy&#xD;
             (i.e.&#xD;
&#xD;
        myocardial ischemia or infarction, arterial thrombosis, pulmonary emboli)&#xD;
&#xD;
          -  Mean Qtc with Bazetts correction &gt; 470 msec in screening ECG, or a history with&#xD;
             familial long QT syndrome&#xD;
&#xD;
          -  Significant haemorrhage (&gt;30 ml bleeding/episode in the last 3 months) or haemoptysis&#xD;
             (&gt;5 ml fresh blood in previous 4 weeks)&#xD;
&#xD;
          -  History of impairment of gastrointestinal function or -disease that may significantly&#xD;
             impair the absorption of oral drugs (i.e. uncontrolled nausea, vomiting, diarrhoea,&#xD;
             malabsorption syndrome, bowel obstruction, or inability to swallow tablets)&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Concomitant use medication that may significantly affect hepatic cytochrome P450 drug&#xD;
             metabolizing activity by way of enzyme induction or inhibition &lt; 2 weeks if the first&#xD;
             dose and throughout the study period (see Appendix 2)&#xD;
&#xD;
          -  Other concomitant anti-cancer therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.M.L. van Herpen, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCN st Radboud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>C.M.L. van Herpen, Md, Phd</last_name>
    <phone>0031 24 3610353</phone>
    <email>c.vanherpen@onco.umcn.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Nijmegen st Radboud</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>C.M.L van Herpen, Md, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sunitinib</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

